Positive CHMP-Recommendation for Nivolumab for the Treatment of Patients with pre-treated local advanced or metastatic Urothelial Carcinoma

[Anonymous]

ONCOLOGY RESEARCH AND TREATMENT, 2017; 40 (6): 389